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A B S T R A C T Individuals with cancer have pre-
viously been shown to have abnormal chemotactic
responsiveness. Surgical removal of the tumor often
resulted in normalization of monocyte function, which
suggests that human neoplasms might inhibit mono-
cyte chemotaxis by release of soluble mediators. We
therefore examined the effects of cancerous effusions
on monocyte polarization, i.e., the rapid change in
monocyte morphology from round to a triangular
"motile" configuration in response to chemoattractants.
All 17 malignant effusions, representing 15 tumor
types, inhibited monocyte polarization induced by
the chemoattractant N - formyl - methionyl - leucyl -
phenylalanine by 45-89% (mean 55.9+12.7%, P
< 0.01) in blinded assays. None of 17 benign effusions
significantly inhibited polarization (0-15%, mean
6.2+±4.2%). Dilutions of cancerous effusions as low as
1:200 produced inhibition that was time, temperature,
and dose dependent. Monocyte polarization induced
by activated serum or by chemotactic lymphokine was
also blocked by cancerous effusions. The inhibitory
activity affected the monocyte directly, and did not
destroy the chemoattractant or block the polarization
of granulocytes to chemotactic factors. High pressure
liquid chromatography of five cancerous fluids re-
vealed three peaks of inhibitory activity: -200,000,
46,000-+13,000, and 21,000+3,000 daltons. Fractiona-
tion of noncancerous effusions revealed only small
amounts of the highest molecular weight inhibitory
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activity. The inhibitory activity in cancerous effusion
was heat stable (56°C, 30 min), trypsin sensitive, and
could be absorbed by three different monoclonal
antibodies reactive to P,5(E), a structural component
of type C retroviruses. In contrast, six monoclonal
antibodies with other specificities had no effect on the
inhibitors of polarization. This study demonstrates that
human cancerous effusions contain novel proteins that
are potent inhibitors of monocyte function and that are
recognized by antibodies reactive to the P,,(E) com-
ponent of retroviruses. By producing such factors,
tumor cells may subvert monocyte-mediated sur-
veillance.
INTRODUCTION
Macrophages, working alone or in concert with
lymphocytes, can destroy cancer cells in vivo and in
vitro (1, 2). Few macrophages, however, are generally
found within progressively growing tumors, and their
numbers are often inversely related to the tumor's
metastatic potential (3-5). Moreover, cancer patients
frequently have abnormally functioning monocytes,
which can regain normal function after cancer therapy
or tumor removal (6-10). Thus, it has been hypothe-
sized that cancer cells may produce factors that alter
monocyte-macrophage functions, thereby subverting
immune surveillance (11). Indeed, in rodents, neo-
plasms produce agents which inhibit macrophage
chemotaxis in vitro and macrophage accumulation in
vivo (12-15).
A major barrier to determining the effects of neo-
plasms on mononuclear phagocyte function in humans
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has been the lack ofa suitable assay. Previous monocyte
function studies, including chemotaxis (6-10), ad-
herence (16), tumor cytotoxicity (5), and superoxide
production (17), have demonstrated variable macro-
phage abnormalities in cancer patients, but the assays
employed have been relatively cumbersome, with no
sharp differentiation between cancerous and noncan-
cerous conditions.
In this study, we utilized a new assay, quantification
of monocyte polarization to chemoattractants (18), to
determine whether human cancerous effusions contain
factors that affect monocyte function. Polarization is
defined as a morphological change in monocytes from a
round to a triangular, "motile" configuration. This
occurs within minutes after the exposure of the cells to
chemoattractants. Effusions from patients with can-
cerous and noncancerous conditions were screened for
their ability to affect the ability ofmonocytes to polarize
in response to chemotactic stimuli. Inhibitors of polari-
zation were found in all cancerous effusions studied
and were characterized in terms of their biological,
physical, and antigenic properties.
METHODS
Patient population. Most of the patients in this study had
pleural or peritoneal effusions due to cancerous or other
conditions, and they underwent paracentesis for clinically
indicated diagnostic or therapeutic reasons. All cancerous
effusions were cytologically proven. The patients were from
the Durham Veterans Administration Hospital, the Duke
University Medical Center, or North Carolina Memorial
Hospital. The individuals with cancer or nonmalignant dis-
eases (Table I) were quite similar when compared by age, sex,
and nutritional status. The average serum total protein and
albumin levels for the two groups were, for cancer patients,
total protein, 6.0+1.0 gldl and albumin, 3.0+0.7 g/dl; and, for
noncancer patients, total protein, 6.7+0.4 g/dl and albumin
2.9+0.8 g/dl. Most patients (90%) were receiving some
medications, but there were no consistent differences in those
received by the two groups. The most commonly used
medications were narcotics, hypnotics, vitamins, thiazides,
and aminophylline. The only patients with culture-proven
infection were two with empyema and one with peritonitis.
These individuals as well as two others were receiving
antibiotics. No patients in the cancer group had received
either chemotherapy or radiation therapy for at least 2 mo
before paracentesis. 8 of 22 cancer patients, however, had
these treatments in the past. Most nonovarian cancer patients
had metastatic diseases; 13 of 17 had metastases to several
anatomic locations.
Collection of effusions. Fluids were collected in non-
heparinized sterile containers and placed at 40C or on ice.
Samples were then centrifuged at 10,000g for 5-10 min to
remove cells and particulate matter. Effusion pH ranged
from 7.2 to 7.5 and the values were unrelated to diagnosis.
The pH were standardized to 7.0, the pH used for polariza-
tion and chemotaxis assays, and the fluids stored at -700C
until tested. The absorbance at 280 nm for all fluids was
determined as an index of protein content.
Isolation of monocytes or granulocytes. Mononuclear
leukocytes and granulocytes were isolated from the blood of



















































































































































Briefly, we mixed heparinized venous blood 1:1 with 3%
(wt/vol) dextran (T500, Pharmacia Fine Chemicals, Div. of
Pharmacia, Inc., Piscataway, N. J.), allowing 20 min for sedi-
mentation at room temperature. A mononuclear cell band was
isolated from the plasma/supernate by the Ficoll-Hypaque
density gradient method (19). The mononuclear cells were
removed and washed with Gey's balanced salt solution con-
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TABLE I
Sources of Effusions
Diagnosis Source Age Sex
taining 2% bovine serum albumin and sodium bicarbonate
(GBSS, pH 7.0, Flow Laboratories, Inc., Rockville, Md.)' at
4°C and 400g for 15 min. After resuspension in GBSS, the
cells were counted with a hemacytometer. The monocyte
concentration was determined by staining for myeloper-
oxidase (20). The percentages of peroxidase-positive cells
and monocytes as determined morphologically with a Wright-
Giemsa stain were similar, -30±10%, depending on the
donor. Granulocytes were isolated from the cell pellet of the
Ficoll-Hypaque density gradient as previously described (19).
Chemotactic peptides and other reagents. N-formyl-
methionyl-leucyl-phenylalanine (FMLP) was obtained from
Sigma Chemical Co., St. Louis, Mo. Zymosan-activated
human serum and lymphocyte-derived chemotactic factor
were prepared as previously described (21).
Polarization assay. The percentage of monocytes or
granulocytes that polarized in the presence of a given
stimulus was measured by incubating the cells (106/ml mono-
cytes or polymorphonuclear leukocytes [PMN] in GBSS) at
37°C with the stimulus in a polypropylene tube (12 x 75 mm;
Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard,
Calif.). At times ranging from 1 to 30 min, 0.01 M ice-cold
phosphate-buffered formaldehyde (10% vol/vol; pH 7.2) was
added to each tube to fix the cells, in either a polarized or
unpolarized state (18, 22). Cell suspensions were kept at 40C
until examined by phase-contrast microscopy. All assays were
performed in duplicate and 200 cells from each tube were
examined under x400 magnification with a hemocytometer.
The percentage of total cells assuming a bipolar configura-
tion was determined.
Because the monocyte suspensions also contained lympho-
cytes, the percentage of polarized monocytes was determined
by the formula: % monocytes polarized = (% total cells
polarized/% peroxidase positive cells) x 100. Lymphocytes
do not polarize in this assay (18).
Because the granulocyte suspensions were >98% granulo-
cytes, the percentage of total cells polarized was used as
the actual percentage of granulocytes polarized.
Inhibition of polarization. The ability of effusions to
inhibit polarization to a chemotactic stimulus was tested by
preincubating the fluids at a final concentration of 10.0, 2.0,
or 0.2 absorbance 280 nm U/ml GBSS with monocytes (106/ml)
or granulocytes (106/ml) for 10 min at 37°C. The chemotactic
stimulant, at a concentration that induced maximum polari-
zation, was then added to the cells for an additional 7.5 min
at 37°C. Ice-cold buffered formaldehyde was then added to
stop the reactions. All effusions (cancerous and noncan-
cerous) were tested blindly and in duplicate.
Inhibition of chemotaxin-induced polarization was then
calculated, after subtraction of background polarization
(polarization in presence of GBSS alone), as: % inhibition
= (chemotaxin polarization with buffer - chemotaxin polar-
ization with effusion/chemotaxin polarization with buffer)
x 100.
Inhibition of chemotaxis. To test fluids for ability to
inhibit chemotaxis induced by FMLP, a modification of the
leading front chemotaxis assay was used (23). Monocytes
(1.5 x 106/ml) were preincubated with the indicated effusion
at room temperature for 10 min. This mixture was then added
to the top compartment of a blind-well chemotaxis chamber
(21). The lower coinpartment contained the effusion with
'Abbreviations used in this paper: CFI, chemotactic fac-
tor inactivators; FMLP, N-formyl-methionyl-leucyl-phenyl-
alanine; GBSS, Gey's balanced salt solution; HPLC, high-
pressure liquid chromatography; PMN, polymorphonuclear
leukocytes; RLV, Rauscher leukemia virus.
FMLP (10 nM). A nitrocellulose filter (50-Mm pore size,
Millipore Corp., Bedford, Mass.) separated the compartments.
Chambers were incubated for 90 min at 37°C. Cancerous
and noncancerous fluids were tested blindly. Counting of
triplicate filters, 10 fields per filter, was done by oil immersion
(x 1,000). Distance (in microns) of migration into the filter by
the leading front of cells (i.e., two furthest migrating cells in
the same plane) was measured by the semiautomated
method of Turner (24).
Effusion fractionation by high-pressure liquid chromatog-
raphy (HPLC) or ultrafiltration. Cancerous and non-
cancerous effusions were fractionated by HPLC. Two silica-
based HPLC columns were coupled in series (Micropak
TSK 3000 SW, 7.5 mm x 50 cm, followed by Micropak TSK
2000 SW, 7.5 mm x 50 cm, Varian Associates, Inc., Instrument
Group, Palo Alto, Calif.). Liquid phase for all chromatographic
runs was 0.15 M NaCl with a flow rate of 1.5 ml/min. A
100-,ul sample was fractionated, and eluted proteins were
monitored by absorbance at 254 nm. Individual column frac-
tions, kept on ice, wvere then assayed for stimulation or
inhibition of polarization. Approximate molecular weights
corresponding to the inhibitory and stimulatory fractions
were determined by the method of Andrews (25).
Ultrafiltration using Amicon CF25 centriflo membrane
cones (25,000 mol wt cutoff, Amicon Corp., Scientific Sys.
Div., Lexington, NMass.) was also used to fractionate effusions.
Effusions were standardized to 40 absorption 280 nm U/ml by
dilution with phosphate-buffered saline (p1I 7.0). Small por-
tions (3-6 cm3) vere filtered through the Amicon membranes
by centrifugation at 4°C and 400 g for 60 min. Repeat absorb-
ance 280 measurements were done on the low-molecular
weight fractions. Dilutions of 1/5, 1/100, and 1/200 were made
from the low-molecular veight fractions, and these were
tested for stimulation or inhibition of polarization.
Sepharose-coupled trypsin and trypsin inhibitor. Bovine
pancreas trypsin and soybean trypsin inhibitor (Sigma Chemi-
cal Co.) were 1)oth coupled to cyanogen-bromide activated
Sepharose 4B (Pharinacia Fine Chemicals). Material to be
tested wvas incubated for either 30 or 60 min with the coupled
Sepharose at a ratio of 0.1 ml Sepharose to 0.9 ml material.
The Sepharose was removed by centrifugation.
Antibodies and other reagents. Monoclonal antibodies to
murine leukemia virus P,5(E) (both IgG2a and IgG2b), murine
leukemia virus GP70 (IgG2a and IgG2b), and human Ia were all
purchased from New England Nuclear, Boston, Mass. Three
different antibodies to P,5(E) are designated as aP15(E)a,
aPi5(E)b, and aPis(E)c; and tvo different antibodies to GP70
are designated aGP7ob anid aGP70e. The isolation, characteriza-
tion, and specificity of these antibodies have been previously
described (26). Monoclonal antibody-producing hybrid cell
lines were obtained by fusion of a BALB/c mouse myeloma
line with spleen cells from 129 or C57 BL/6 mice immunized
with AKR leukemia cells. The resultant cell lines produce 7S
IgG antibodies. The anti-P,5(E) antibodies react with the
murine leukemia virus protein P15(E) or its degradation
product, P12(E), but not with the glycoprotein, GP7,. The anti-
GP70 antibodies react with GP70 but not with P15(E) or P12(E).
Murine IgG2a was kindly supplied by Dr. John Cambier of
Duke University. Murine ascites fluids cointaining mono-
clonal antibodies (5-10 mg/ml) against human lymphoid cells
(anitibodies designated as 4F2 and 5E9) (27) and a myeloma
ascites fluid of tlhe immunoglobulin subclass IgG, were
kindly supplied by Dr. Barton Haynes of Duke University.
Formalin-fixed Staphylococcus aureus (IgGsorb) was ob-
tained from The Enzyme Center, Inc., Boston, Mass. Purified
murine Rauscher leukemia virus (RLV) was supplied by Dr.
John Cole, Office of Program Resources and Logistics, Na-
tional Cancer Institute.
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Protein determinations. Protein concentrations of ultra-
filtrates were determined by the method of Lowry et al. (28).
Statistical significance. Statistical analyses were done on
each daily experiment, comparing individual benign and
malignant samples with FMLP controls (analysis of variance
and Q-test). These data were used to compare the cumulative
group of malignant fluids with the cumulative group of
benign fluids (chi-square).
RESULTS
Ability of effusions to induce monocyte polariza-
tion. To determine whether effusions contained in-
hibitors of monocyte polarization to chemoattractants,
it was first necessary to test them for their inherent
ability to induce polarization. Noninfected benign and
malignant fluids exhibited little intrinsic polarizing
activity (Table II). These effusions also did not cause
TABLE II
Monocyte Polarizing Activity in Various Effusions*
Monocytes
Material tested nt Con.ceintration polarized§
%±SE
Gey's medium alone 7 10.0±5.2
Phosphate-buffered saline
alone 4 7.0±+-2.4
FMLP 7 10.0 nM 57.3±7.4
Zymosan-activated 2 0.5% 50.0±+-2.8
human serum 2 5.0% 67.0±1.4
Lymphocyte-derived 2 5.0% 37.0±1.4
chemnotactic factor 2 20.0% 62.0±1.4
Benign effusions 12 10.0 abs 280 nnm 17.6±8.9
4 2.0 Abs 280 nm 6.8+±3.1
4 0.2 Abs 280 nm 4.5±2.4
Infected effusions 3 10.0 abs 280 nm 41.4±7.3
3 2.0 abs 280 nm 39.0 ±6.1
3 0.2 abs 280 nm 30.0±4.8
Nonovarian malignant 16 10.0 abs 280 nm 19.5±6.5
effusions 8 2.0 abs 280 nm 10.1±3.4
7 0.2 abs 280 nm 6.9±3.1
Ovarian malignanlnt ascites 5 10.0 abs 280 nm 55.3±3.7
5 2.0 Abs 280 nm 41.0±4.1
5 0.2 abs 280 nm 34.8±3.7
* The inherent capabilities of the various effusions to cause
moniocyte polarization were compare(d with the capabilities
of known chemotaxins.
I n,, number of samples tested, each in duplicate.
§ Monocytes (106/ml) were incubated with the indlicated
miiaterial for 17.5 min at 37°C, fixed, and the percentage of
polarized monocytes in duplicate tubes determined by phase-
contrast microseopy (x400): % monocytes polarized = (% total
cells polarized/% peroxidase positive cells in initial cell
suspension) x 100.
polarization at times ranging from 1 to 30 min. Ovarian
cancer ascites fluids, however, when tested at the
highest concentration, induced near-maximum polar-
ization. Moreover, three of three infected benign fluids
(bacterial empyema or peritonitis) induced substantial
polarization. Therefore, whereas most effusions could
be screened for inhibition of polarization, unfraction-
ated ovarian cancer ascites and infected effusions
could not, since the polarizing activity in the fluids
would "mask" any inhibitors also present.
Inhibition of polarization by malignant effusions.
To test whether cancerous fluids contained inhibitors
of monocyte polarization, normal monocytes were
incubated with the various fluids and the cells then
further incubated with FMLP at a maximum stimula-
tory concentration (Fig. 1). At the highest concentra-
tion tested all 16 nonovarian cancerous effusions in-
hibited polarization (inhibition 55.9±12.7%, P < 0.01),
whereas none of the 17 benign fluids inhibited sig-
nificantly (inhibition 6.7±4.2%) at corresponding con-
centrations. One cancerous effusion could not be tested
at the highest concentration, because it caused clump-
ing of cells.
In the polarization assay the extent of inhibition
produced by malignant effusions was dependent on
temperature and incubation time. Maximal inhibition
required 30 min at 25°C but only 10 min at 37°C. Benign


















FIGURE 1 Effect of 17 cancierous (0) and 17 noncancerous
(@) effusions on monocyte polarizationi. Monocytes (106/ml)
were preincubated with various effusion concentrationls for
10 min at 37°C, stimulated with 10 nM1 FMLP for 7.5 mill,
fixed, and the percentage of polarized moniocytes (leterm-ined.
After subtraction of background (cells with buffer only), per-
centage of inhibition of polarizationi was calculated as: N
inhibition = (FMLP polarization with buffer - FMLP polatr-
ization with effusion/FMLP polarization with buffer) x 100.
At 10.0 absorbance 280 nm, all cancerous effusions, but no
noncancerous effusions, caused statistically significant in-
hibition of FMLP-induced polarization (P < 0.01 by analysis
of variance, Q-test, and chi2).
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To determine whether the inhibitors present in can-
cerous effusion could reverse polarization, normcal
moniocytes were first stimulated with FMLP for 10 min,
thenl cancierouis effuisionI was added and the cells in-
cubated for varying lengths of time before being fixed.
The results of two experiments (data not shown) indi-
cated that addition of cancerous effusion to polarized
monocytes reversed that polarization to the same levels
obtained by preincubation of the cells with effusion,
and that this reversal was complete within 15 min after
the effusion was added.
Fluids from patients with a wide variety of solid
tumnors contained inhibitory activity. Even chylous
ascites (mixed histiocytic-lyymphocytic lymphoma) and
leukemic (acute myelomonocytic) pericardial effusion
contained inhibitory activity. Cerebrospinal fluid from
a patient with carcinomatous meningitis due to meta-
static colon cancer and malignant breast cyst fluid were
also inhibitory. As anticipated, unfractionated malig-
nant ovarian ascites fluid did not appear to depress the
response to FMLP, because the ascites itself induced
polarization, particularly at high concentrations (Table
III). At lower concentrations, however, the polarizing
activity ofone ofthe two ovarian ascites was diluted out
and inhibitory activity became evident.
Inhibition of mtonocyte chemotaxis by malignant
effusions. Several effusions were assayed for their
ability to inhibit monocyte chemotaxis. The mean in-
hibitory activity, at each dose tested, was greater in
cancerous fluids (Fig. 2). Even at the highest dose
tested, however, only 11 of 17 malignant fluids were
inhibitory (59.7+25.7%, P < 0.05). Three of nine be-
TABLE III
Effect of Ultraifiltratiotn oni Polarizing anid Inzhibitory Activities of Effusions
Diltitioni Monocvte Inhibitioni of
Sotirce of efltisioll tester1 Ultrafiltration* polarizationt FNILP polarization§
%±SE
Ovatrian cacieer 1:5 49.7±5.0 0±9.0
ascites 1 1:20 36.4±3.2 9.0+2.4
1:200 3.2±0 33.2±14.6
1:5 + 3.2± 10.0 41.3± 10.1
1:20 + 0±3.2 85.4±18.2
1:200 + 7.0± 1.0 41.7±6.1
Ovariain cancer 1:5 43.2±8.5 0±0
ascites 2 1:20 26.4± 1.8 0±0
1:200 3.2± 10.0 0±0
1:5 + 0±1.6 41.3±1.9
1:20 + 5.0± 1.8 41.7±6.1
1:200 + 0± 1.7 49.5±10.2
Bacterial peritonitis 1:5 54.0±7.0 0+0
ascites 1:20 24.0±2.8 2.0±1.1
1:200 18.0±2.8 0±0.6
1:5 + 0±2.8 2.0± 1.6
1:20 + 0±4.1 2.0±0.9
1:200 + 0± 1.6 0±0.7
* The effusions were standardized to 40 absorbance 280 U/ml and individually ultrafiltered
through an Amicon CF25 centriflo cone (<25,000 mol wt exclusion limit) at 400 g and 4°C for
60 min; + denotes ultrafiltered fraction; -, no ultrafiltration.
I The fluids at the indicated dilutions were incubated with monocytes (106/ml) for 17.5
min at 37°C, fixed, and the percentage ofpolarized monocytes in duplicate tubes determined
by phase-contrast microscopy (x400): %N monocytes polarized = (% total cells polarized/
% peroxidase positive cells (monocytes) in initial cell suspension) x 100.
§ The ability of various effusion dilutions to inhibit monocyte polarization induced by
FMLP was determined by incubating cells with fluid for 10 min at 37°C, challenging
with 10 nNI FMILP for an additional 7.5 min at 37°C, fixing the cells, and examining
them using phase contrast microscopy (x400). Inhibition of polarization to FMLP was
ctalculated, after subtraction of background polarization (to buffer alone), as in Fig 1.




















FIGuRE 2 Effect of 17 cancerous (0) and 9 noncancerous
(0) effusions on monocyte chemotaxis. Monocytes (1.5 x 106/
ml) were preincubated with the indicated effusion concen-
tration for 10 min at room temperature. This mixture, placed
in the upper compartment of a chemotaxis chamber, was
separated by a 5.0-,um pore-size nitrocellulose filter from 10
nM FMLP placed in the lower compartment in the same con-
centration of effusion. The chambers were incubated for 90
min at 37°C. The distance of migration of the leading front
of monocytes through the stained filters was measured. After
subtraction ofbackground (migration of cells to buffer alone),
percentage of inhibition of chemotaxis was calculated as:
% inhibition = (FMLP chemotaxis with buffer - FMLP
chemotaxis with effusion/FMLP chemotaxis with buffer)
x 100. At 10.0 absorbance 280 nm, 11 of 17 cancerous and 3 of
9 noncancerous effusions caused statistically significant
inhibition of chemotaxis (P c 0.05 by analysis of variance and
Q-test).
nign fluids also displayed inhibitory activity (>20% in-
hibition). It is unlikely that chemotactic deactivation
was responsible for the inhibition of chemotaxis
caused by either benign or malignant effusions, be-
cause only some of the inhibitory effusions contained
chemotactic activity and only at the highest concentra-
tions tested (10 absorbance 280 nm U/ml). The presence
of intrinsic chemotactic activity did not distinguish be-
tween benign and malignant effusions nor did it cor-
relate with the degree of inhibition of chemotaxis to
FMLP. In any case, the chemotaxis assay was not as
effective as the polarization assay in distinguishing
between cancerous and benign fluids.
Fractionation of effusions by HPLC. Several effu-
sions were fractionated by HPLC to determine whether
polarization inhibitor(s) and stimulant(s) were sep-
arable by molecular weight. This fractionation would
also indicate whether any inhibitory activity in ovarian
cancer ascites or infected benign effusions was masked
by polarizing activity present in the unfractionated
state. HPLC of malignant ovarian ascites revealed a
major peak that stimulated polarization, at mol wt
- 200,000 (Fig. 3). A high-molecular-weight inhibitory
peak was also found. The major inhibitory activity,
however, was found in two peaks: one eluting just
before ribonuclease, the other with ovalbumin. The
approximate molecular weights of these peaks, deter-
mined by the technique of Andrews (25), were 20,000
and 45,000.
Column fractionation ofmalignant melanoma pleural
fluid confirmed three broad but distinct inhibitory
peaks (Fig. 4A). The unfractionated fluid did not
polarize, and stimulatory fractions were not found (data
not shown). Column fractionation ofbenign pulmonary
infarction pleural fluid uncovered only the highest
molecular weight inhibitory peak (Fig. 4B). No polar-
izing peaks were found. The unfractionated benign
effusion neither inhibited nor stimulated polarization.
HPLC has revealed the highest molecular weight
peak as well as the two low molecular weight inhibitory
peaks in all five malignant effusions tested (melanoma
pleural, liposarcoma pleural, lung adenocarcinoma
pleural, prostate adenocarcinoma pleural, and ovarian
peritoneal). Only the highest molecular weight peak
(.200,000) was found in fractions from four benign
effusions (uremic pleural, pulmonary infarction pleural,
heart failure pleural, and cirrhosis peritoneal) and in
four sera from patients without cancer (results not
shown). The approximate mean molecular weights of
the three inhibitory peaks in the malignant effusions
were >200,000; 46,000±+13,000 (range 36,000-52,000);
and 21,000±3,000 (range 18,000-25,000).
Since the polarizing activity of ovarian ascites was
of high molecular weight, and most of the inhibitory
activity of low molecular weight, Amicon cone ultra-
filtration (mol wt < 25,000) was used to separate these
activities. In two oftwo ovarian samples, ultrafiltration
resulted in significant inhibitory activity and no polar-
izing activity in the ultrafiltrate (Table III). One in-
fected benign effusion (bacterial peritonitis) was also
ultrafiltered to see whether any low molecular weight
inhibitors could be separated (Table III). The low
molecular weight portion did not contain inhibitory
activity.
Site of action of inhibitors of polarization. To
determine whether the inhibitory activity of cancer
fluids was directed at the chemoattractant or at the
cell, experiments using preincubation techniques were
designed. Malignant fluids were preincubated at 37°C
for 10 min with either FMLP alone or the monocytes
alone. After this, either FMLP or monocytes were
added to the incubation mixtures for an additional 7.5
min at 37°C. The cells were then fixed, and polariza-
tion was measured. The results suggested that the
inhibitory factor(s) affected the monocytes rather than
FMLP (Table IV), because preincubation of fluids
with cells resulted in inhibition, whereas preincuba-
tion of fluids with FMLP did not.
To test further whether the inhibitors were cell-
directed, monocytes (in 5 ml) were preincubated with
fluid ultrafiltrates and then washed four times with
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FIGURE 3 Separation by HPLC of cancerous ovarian ascites. A 100-,ul sample of undiluted
ascites was chromatographed on two silica-based columns coupled in series. Fractions of 1.0 ml
each were monitored for absorbance at 254 nm (0). Individual fractions were assayed for
stimulation (0) or inhibition (m) of monocyte polarization.
50 ml of buffer. Upon stimulation with FMLP, mono-
cyte polarization was still strongly inhibited in cells
that had been exposed to cancerous ultrafiltrate and
then washed (Table V).
Inhibition ofpolarization induced by several chemo-
attractants. To see whether malignant fluids inhibit
polarization to chemoattractants other than FMLP,
zymosan-activated human serum, or lymphocyte-
derived chemotactic factor was used as the chemotactic
factor. Polarization induced by all three agents was
inhibited by malignant but not by benign effusions
(Table VI).
Effects ofeffusions on the polarization ofPMN. To
test the specificity of the inhibitory activity for mono-
cytes, malignant effusions were also incubated with
PMN, and FMLP-induced polarization was measured.
No inhibition of PMN polarization occurred, despite
varying malignant fluid concentration, FMLP concen-
trations, and incubation times (Table VII).
Temperature and protease sensitivity. Ultrafiltered
effusion from a patient with cancer was incubated for
varying times at 370, 560, or 70°C and then tested for its
effects on monocyte polarization. An ultrafiltrate that
had been kept on ice was used as control. Incubation
for 1 h at 37°C resulted in no loss of activity while 2 h
resulted in a 30% decrease in activity. Activity was
stable after 30 min at 56°C but was only half as potent
after 60 min. Incubation at 70°C for even 10 min resulted
in the loss ofinhibitory activity. Ultrafiltered malignant
effusion was tested for protease sensitivity by incuba-
tion with trypsin coupled to Sepharose. Incubation
for 30 or 60 min at 220C caused a decrease in the in-
hibition of polarization from 60% to 9 and 10%, re-
spectively. Incubation with trypsin inhibitor coupled
to Sepharose had no effect on the inhibitory activity.
Removal of inhibitory activity by monoclonal anti-
body. The ultrafiltered effusions (containing 150-
250 ,ug protein/ml) from eight different cancer patients
were individually incubated with monoclonal antibody
reactive to murine leukemia virus P,5(E), or with other
antibody preparations, adjusted to contain the same
amount of protein as the anti-P,5(E). The antibodies
were then removed by adsorption to formalin-fixed
S. aureus, and the materials tested for effects on mono-
cyte polarization (Table VIII). There was a marked
decrease (P <0.01) in the inhibitory activity of the
























































































FIGURE 4 Separation by HPLC ofcancerous pleural effusion
due to melanoma (A) and noncancerous pleural effusion due
to a pulmonary embolus (B). A 100-,ul sample of undiluted
effusion was chromatographed on two silica-based columns
coupled in series. Fractions of 1.0 ml each were monitored
by absorbance at 254 nm (0). Individual fractions were
assayed for inhibition (m) or stimulation (not plotted because
they were negligible) of monocyte polarization.
filtrates absorbed with monoclonal antibody to P15(E).
Anti-P15(E) antibodies of either the IgG2a or IgG2b sub-
classes were capable ofabsorbing the inhibitory activity
even though they are reported to react with different
determinants on the P,5(E) molecule (26). There was no
significant decrease in the inhibitory activity of the
filtrates after absorption with mouse IgG2a, monoclonal
antibody to the murine leukemia virus glycoprotein
GP70, monoclonal antibody to human Ia antigen, a
murine IgG, myeloma ascites fluid, or two ascites
fluids containing monoclonal antibodies reactive with
human lymphoid cells.
A low molecular weight (<25,000) extract of soni-
cated RLV, a virus known to contain P15(E), was also
tested for inhibition ofthe polarization ofhuman mono-
TABLE IV
Monocyte Polarization After Preincubation of Cells or
Chemoattractant with Cancerous Ascites
Inhibition of polarizationt
Material preincubated Ascites Experiment Experiment
with ascites* concentration 1 2
abs 280 nm %-SE
Monocytes 10.0 67.6±2.8 67.0±4.2
2.0 51.1±1.4 5§
0.2 46.6± 1.4 22.0±2.8
Chemoattractant (FMLP) 10.0 0±0 0±4.6
2.0 0±3.1 5§
0.2 0±0 9.1±1.4
* Ascites at the indicated concentrations was preincubated in
duplicate tubes with either monocytes or chemoattractant
(10 nM FMLP) for 10 min at 37°C. Either monocytes or
chemoattractant were added for an additional 7.5 min at 37°C,
the cells fixed and examined by phase-contrast microscopy
(x400).
t Inhibition of polarization to FMLP was calculated, after
subtraction of background polarization (to buffer alone), as
in Fig. 1.
§ Not determined.
cytes (Table VIII). The extract significantly inhibited
monocyte polarization and the inhibitory activity was
absorbed by monoclonal anti-P,5(E) antibodies of both
the IgG2a and IgG2b subclasses. Murine IgG2a and
monoclonal anti-GP70 had no effect on this inhibitory
activity.
TABLE V
Monocyte Polarization after Washing of Cells Preincubated
with Ultrafiltrates of Effusions
Inhibition of polarizationt
Unwashed Washed
Source of effusion* monocytes monocytes
%-SE
Squamous carcinoma
pleural effusion 55.5+4.0 48.3+3.1
Lymphoma pleural effusion 70.4 +4.0 61.0+±8.5
Cirrhosis ascites 5.5+2.1 5.5±3.8
Congestive heart failure
pleural effusion 0.0±+1.2 7.0±4.5
* Ultrafiltrates of effusions (diluted 1:5) were preincubated
with normal monocytes for 10 min at 37°C. The cells (5 ml)
were then washed four times in buffer (50 ml), stimulated with
chemoattractant (10 nM FMLP) for 7.5 min at 37°C, fixed,
and then examined by phase-contrast microscopy (x400).
t Inhibition of polarization to FMLP was calculated, after
subtraction of background polarization (to buffer alone), as
in Fig. 1.



















Effect of Effusions otl Monocyte Polarization Induced by Various Chemnoattractants*
% Inhibition of polarizationt
Zymosan-activated Lymphocyte-derived
Source of effusions Concentration FMLP human serum chemotactic factor
absorbance 280 nm 10 nM 5% vollvol 20% vollvol
Melanoma ascites 10.0 98.0±+1.4 71.8±+13.1 83.0+9.8
2.0 77.0±2.8 67.5±+19.1 62.2±+1.4
0.2 0.0±10.6 20.2+6.1 21.5+3.2
Mlelanosarcoma 10.0 81.2+±9.8 75.6+12.1 100.0+0.0
pleural effusion 2.0 62.0+0.7 67.7+9.8 55.4±4.5
0.2 8.0+0.0 0.3+0.7 10.2+2.1
Squamous carcinoma 10.0 91.6+12.7 77.7±14.0 97.7+3.5
pleural effusion 2.0 46.1+11.3 8.6+3.2 86.7+9.8
0.2 7.7+6.8 8.6±3.2 52.7±4.5
Cirrhosis ascites 10.0 0±+1.4 0±0 0±+1.3
2.0 0±0 0±0 20.5±9.7
0.2 0±0 0±3.2 0±1.3
Congestive heart failure 10.0 0± 1.8 0±0 10.0±2.4
pleural effusion 2.0 0±0 0+2.8 0±0
0.2 0±0 0±0 0±1.3
* Variouis cancerous or noncanicerous effusions were preincubated with monocytes (106/ml) for 10 min
at 37°C, the cells were then challenged with the indicated chemoattractant for an additional 7.5 min
at 37°C, fixed, and examined by phase-contrast microscopy (x400).
t Percent inhibitioni of polarization to the indicated chemoattractant (Ctx) was calculated, after
subtractioni of background polarization (to buffer alone), as: % inhibition = (Ctx polarization with
buffer - Ctx polarization with effusion/Ctx polarization with buffer) x 100.
Four malignant effusions that had not been ultra-
filtered were also tested before and after absorption
with anti-P,5(E) (Table IX). The monoclonal anti-P15(E)
removed a significant portion of the activity from these
fluids. Murine IgG2a or monoclonal anti-GP70 had no
significant effect on inhibition.
To see whether the inhibitors which affected polari-
zation and chemotaxis were antigenically related, five
effusions which inhibited chemotaxis were preincu-
bated with buffer alone or with buffer containing either
monoclonal anti-P,5(E) or monoclonal anti-GP70. Anti-
body was removed by S. aureu.s absorption and the
fluids were tested for their ability to inhibit chemo-
taxis. The average inhibition of the five effusions after
preincubation with buffer or anti-GP70 was 72 and 77%,
respectively, whereas the fluids absorbed with anti-
P15(E) inhibited chemotaxis by aIn average of onlly 33%
(data not shown).
In the abseniee of FMLP, effusions or ultrafiltrates
treated with anti-P15(E) plus S. aureus had no polarizing
or chemotactic activity. Thus, the ability of anti-P15(E)
to block the inhibitory activity in malignant effusions
was not due to the generation of polarizing or chemo-
tactic activity.
DISCUSSION
Although the concept of immune surveillance, as a
mechanism ofhost resistance to cancer, offers hope that
highly specific, more effective, and less toxic therapies
for tumors can be developed, extensive clinical im-
munotherapy trials (29, 30) have not yet fulfilled ex-
pectations. In fact, the role of the immune system in
cancer control has been seriously questioned. Many
arguments against immune surveillance, however,
underplay the role of the macrophage. Evidence sup-
porting the importance of the macrophage in resisting
the development and spread of cancer has recently
received increasing attention (11).
Since abnormalities of monocyte activities, par-
ticularly chemotaxis, have been reported in humans
and animals with cancer (6-17), the present study
sought to determine whether inhibitors of monocyte
function were present in human cancerous effusions.
A new assay, monocyte polarization in response to
chemoattractants, proved to be rapid and reproducible
in blind experiments. More importantly, the polariza-
tion assay appears to be sensitive and specific in de-
tecting monocyte inhibitors in the effusions of cancer
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TABLE VII




Effusion Concentration 10-min 10-min 20-min
concentration of FMLP preincubation preincubation preincubation
































10.0 0.01 0±0 -
2.0 0.01 2.2±1.4 -
* Cancerous effusion was preincubated with normal granulocytes (PMN, 106/ml)
or monocytes (106/ml) for 10 or 20 min at 37°C, the cells challenged with FMLP
at the indicated concentrations for 7.5 min at 37°C, fixed and then examined
by phase-contrast microscopy (x400).
I Percentage of inhibition of polarization to FMLP was calculated, after
subtraction of background polarization (to buffer alone), as in Fig. 1.
§ Not determined.
patients. All 17 nonovarian cancerous effusions tested,
but none of 17 noncancerous fluids tested, contained
activity that inhibited polarization. Since ovarian
cancer ascites contained high molecular weight in-
trinsic polarizing activity, inhibitors could only be
found in the ovarian fluid ultrafiltrates or low molecular
weight fractions separated by HPLC. The finding that
ovarian ascites fluids contained polarizing as well as
inhibitory activities suggests that, at least with some
neoplasms, a complex interplay between stimulatory
and suppressive mechanisms may be operative. The
balance between these activities, particularly within
the tumor itself, could be one determinant of the
growth potential of the neoplasm.
A striking finding was the association of these in-
hibitors with 15 varied solid tumors of several cell
types (squamous, adenocarcinoma, undifferentiated,
sarcoma, melanoma, etc.) metastatic from numerous
primary anatomic locations. Even focal exudates in a
patient with leukemia and another with lymphoma
contained inhibitors. One malignant cerebrospinal
fluid sample also contained inhibitory activity, which
suggests that inhibitors can be detected in fluids from a
variety of locations. Variables such as sex, age, medica-
tions, and nutritional status did not correlate with in-
hibitory activity. Chemotaxis experiments revealed
similar inhibitory activity in cancer effusions, but the
polarization assay is more suitable for detecting in-
hibitors of monocyte function.
In characterizing the inhibitory activity by means of
high pressure gel filtration, three fractions of - 2200,000,
46,000+13,000 and 21,000+3,000 daltons were found.
Only the highest molecular weight component was
present in noncancerous effusions or in normal human
serum.
The inhibitory activity found in human cancerous
effusions was biologically potent, being active at dilu-
tions of up to 1:200, and appeared to at least partially
reside in a protein moiety, because the activity of low
molecular weight ultrafiltrates was destroyed by tryp-
sin. This is contrary to the lipid-like inhibitory factor
isolated from cell cultures of human breast cancer or
melanoma (31). The inhibitory factors for monocyte
polarization are cell-directed and monocyte-specific,
in that granulocyte polarization was unaffected. This is
similar to the inhibitors of macrophage chemotaxis
produced by murine neoplasms (12). The human in-
hibitors, moreover, blocked monocyte polarization to
all three classes of chemoattractants tested.
Inhibitors ofmonocyte and granulocyte function had
been previously described in normal serum (32, 33).
Most of the previously described inhibitors have been
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chemotactic factor inactivators (CFI) although cell-
directed inhibitors were also reported. Increased levels
of CFI or cell-directed inhibitors have been found,
however, in sera from patients with noncancerous
diseases such as cirrhosis, sarcoidosis, leprosy, sys-
temic lupus erythematosus, and chronic periodontitis.
Occasional malignant states, especially Hodgkin's
disease, have been associated with increased serum
levels of CFI or cell-directed inhibitors. Kjeldsberg
and Pay (34) described CFI in sera in 19 of 21 patients
with cancer of the lung or prostate. No CFI was found
in 12 controls. Monocyte chemotaxis was also abnormal
in 10 of the cancer patients. In four patients treated
and followed, two treated surgically lost CFI, two
treated chemotherapeutically did not lose CFI. These
CFI and cell-directed inhibitors were described as
larger proteins (4, 7, and 10S sedimentation coefficients)
than those inhibitors described in this paper.
In previous studies we found that potent inhibition
of macrophage accumulation in mice was caused by
the injection of a murine leukemia virus envelope
protein of 15,000 daltons, termed P15(E) (35). The in-
hibitory activities for macrophage accumulation de-
rived from either murine tumors or disrupted murine
leukemia viruses were physiochemically and anti-
genically similar. Antibody raised against disrupted
Friend leukemia virus absorbed the inhibitory activity
for macrophage accumulation isolated from a murine
tumor cell extract (36). Recent studies by other labora-
tories have also demonstrated the immunosuppressive
potential of type C virus structural proteins. Mathes
et al. (37, 38) showed that a 15,000 mol wt protein of
feline leukemia virus could abrogate lymphocyte
blastogenesis and capping in vitro and reduce the level
of antibody formation in vivo. Inhibition of in vitro
lymhocyte transformation by disrupted murine leu-
kemia virus has been demonstrated by Fowler et al. (39).
In the present study we have demonstrated that the
low molecular weight inhibitors of monocyte polariza-
tion in human effusions are similar to the murine in-
hibitor of macrophage chemotaxis derived from neo-
plasms (12). More importantly, a monoclonal antibody
reactive against the P,5(E) component of murine leu-
kemia viruses bound the inhibitory activity derived
from all human cancerous effusions tested. These data
suggest that the human inhibitory factor may have anti-
gens in common with a structural component ofa murine
RNA tumor virus. In addition, extracts of a murine leu-
kemia virus also inhibited human monocyte polariza-
tion and this activity was also absorbed by antibody
to P,5(E). We can not yet estimate, however, the total
extent of the antigenic or structural relationship be-
TABLE VIII
Effect of Various Monoclonal Antibodies on Inhibition of Monocyte Polarization by Ultrafiltrates of Cancerous Effusions*
Ultrafiltrate % Inhibition (-SE) of monocyte polarization by ultrafiltrate from effusion§
preincubated
witht AN A B C" D D E F G H RLV RLV
Media alone 60.8±16.6 63.6+3.2 55.0±1.4 67.6±1.1 62.2±7.2 60.0±4.8 61.1±11.0 46.5±8.6 58.4±4.3 70.9±3.0 66.7±15.5 52.5±3.2
aP,s,(E)a
(IgGO) 16.0±0 0±16.5 12.6±3.2 9.4+0 -1 0±2.8 0±7.8 7.9±1.5 4.3±1.2 - 3.1±1.4 0±7.7
afPjs(E)b
(IgG2b) - 1.0±10.9 - - - - - - - - - 2.0±0.7
aP,,(E)c
(IgGIb) - 11.2±4.6 - - 18.4+0 - - - - 15.4±10.2 - 8.4±7.2
(IgG2.) 63.2±14.2 46.4±1.5 66.6±9.5 63.0+12.3 - - - 52.4±9.0 50.0±0 - - 50.5±2.7
eGP, '
(I;g,b) - 52.2±2.7 - - - - - - - - - 53.0±9.2
IgGz. 67.5±18.3 - 55.0±10.6 63.0+0 - 59.5±1.5 54.5±1.2 57.9±9.0 56.7±12.0 - 65.8±0.9 -
ala 61.±12.3 - 61.2±11.6 69.8+12.3 -
Myeloma IgG, 57.2±4.3 - 55.0±8.5 72.0±1.1 54.7±7.2 - - - - 56.2±8.7
4F2 49.8±3.1 - 59.1±9.6 61.5+3.9 - - - - - - - -
5E9 66.3±13.5 - 50.8±2.0 62.6+8.3 - - - - - - - -
* Ultrafiltrates were prepared from the following effusions by centrifugation through Amicon CF25 centriflo cones: (A) ascites fluid, ovarian carcinoma; (B) ascites
fluid, ovarian carcinoma; (C) ascites fluid, melanoma; (D) pleural fluid, melanoma; (E) pleural fluid, metastatic squamous cell carcinoma of the lung; (F) pleural
fluid, metastatic anaplastic carcinoma of unknown origin; (G) pleural fluid, squamous cell carcinoma of the lung; (H) ascites fluid, lymphoma; (RLV) murine
Rauscher leukemia virus.
t 0.5 ml of the ultrafiltrate was incubated for 15 min at 22°C with 10 Al of GBSS or GBSS containing 7.5 Ag of the appropriate antibody. 25 M1 of formalin-fixed
S. aureus (IgGsorb) was added, the mixture incubated an additional 12 min at 22'C, and the IgGsorb removed by centrifugation at 12,000 g for 2 min.
5 0.1 ml of absorbed ultrafiltrate was incubated for 10 min at 37°C with 0.3 ml of cell suspension containing 4.8 x 105 peroxidase-positive mononuclear cells.
0.1 ml of GBSS or 50 nM FMLP in GBSS was then added to each of duplicate tubes, the tubes incubated an additional 7.5 min at 37C, the cells fixed, and
the percentage of polarized monocytes determined. The percentage of inhibition of polarization to FMLP was calculated, after subtraction of background polar-
ization (to buffer alone), as in Fig. 1.
' These ultrafiltrates were each absorbed with 2.5 jsg of the appropriate antibody.
I Not determined.
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TABLE IX
Effect of Monoclonal Antibodies otn Inhibition of Monocyte Polarization
by Untfractiotnated Cancerous Effusions
Inhibition of miionocyte polarization after preincubation withl
OIP15(E)a aGP,,,b
Experiment Effusion* GBSS (IgG2.,) IgG2. (LgG2.)
%-SE
1 A 54.3±4.3 0±9.8 57.6±t17.9 58.4±13.0
B 47.4±14.2 0±6.6 51.3±5.5 50.4±3.0
C 64.2±1.6 0.7±13.9 49.8±6.3 52.6±3.3
2§ A 53.9±3.3 11.6±11.6
C 84.5±7.7 17.4±24.8 --
D 72.9±0 30.6±12.9 - 78.4±15.5
35 A 66.3±7.8 6.7±2.6 --
C 43.0± 10.3 19.6±2.7 -
D 81.9±5.3 31.5±2.6 - 70.2±9.1
* Effusions tested were as follows: (A) pleural fluid, squamous cell careinioma of the lunig;
(B) pleural fluid, melainomiia; (C) ascites fluiid mlelanioma; (D) pleural fluid, carcinlomal of
the bladder.
t 0.5 ml of effusion was incubated for 15 min at 22°C with 10 ,ul of GBSS or GBSS containing
7.5 ug of the appropriate antibody. 25 Al of IgGsorl) was added, the mixtuire incubated an
additional 12 min at 22°C, and the IgGsorb removed by centrifugationi at 12,000 g for 2 min.
0.10 ml of the absorbed effusion was then incubated for 10 min at 37°C with 0.3 ml of cell
suspension containing 4.8 x 105 peroxidase-positive m-nononuclear cells. 0.10 ml of GBSS or
50 nM FMLP was theni added to each of duplicate tubes, the tubes incuibated ani additional
7.5 min at 37°C, the cells fixed and the percentage of polarizedl cells determined. The percent
inhibition of polarization to FMILP was calcutlated, after subtraction of background polar-
ization (to buffer alone), as in Fig. 1.
§ In these experimenits 15.0 ,tg of the indicated antibodies were used.
11 Not determined.
tween the human and murine material. A majority ofthe
inhibitory activity in unfractionated human cancerous
effusions was absorbed by monoclonal anti-P15(E).
This suggests that the high molecular weight inhibitory
activity detected by gel filtratioin chromatography of
cancer effusions may be either precursor molecules
or aggregates of the low molecular weight inhibitor.
The significance of identifying a protein in human
cancerous effusions bound by antibody reactive with
murine leukemia virus P15(E) is not yet clear. Our data
do not provide evidence that the inhibitory factor in
cancerous effusions is a result of viral infection. The
inhibitory protein could be synthesized upon the dere-
pression of genes in malignant cells that code for a
virally related protein. Alternatively, the protein may
be one produced as part of the membranes of de-dif-
ferentiated cells, whether or not the dedifferentiation
was due to virus infection. P15(E) is an envelope protein
of type C retroviruses and thus is derived from the
host cell's membrane as the virus buds from the in-
fected cell. Thus the dedifferentiating effect of a virus
infection could stimulate the host cell to produce a
naturally occurrinig membrane protein that becomes
incorporated into the viral envelope. Indeed, there is
evidence for widle anitigen cross-reactivity of P,5(E)
isolated from viruses of m-any animiial species including
primate. Thiel et al. (40) have recently demonstrated
that rabbit antiserum against Friend murine leukemia
virus P15(E) was capable of precipitating material
from both primate type C and type D viruses.
Thus, the evidence presented here demonstrates
that potent inhibitory agents that alter monocyte re-
sponsiveiness to chemoattractants are present in human
cancerous effusions. We have not yet determined
whether these inhibitors are present systemically or are
localized to focal tumor microenvironments, although
studies to answer this (luestion are ongoing. Similarly,
a possible correlation between the amiount ofinhibitory
activity with the extent of cancer metastasis or tumor
burden is being iinvestigated. In any case, assaying for
inhibition of monocyte polarization to chemotactic
factors provides an apparently useful assay for dif-
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ferentiating cancerous from noncancerous effusions.
This assay could therefore have considerable diag-
nostic importance. These studies, moreover, support
the concept that clinically apparent neoplasms may
produce potent inhibitors of monocyte function and
thereby sul)vert their destruction by immunological
processes requiring macrophage accumulation. If this
is the case, immunotherapy specifically designed to
counter the inhibition of monocyte response to chemo-
attractants may be more effective than those regimens
currenitly being used.
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